Skip to main content
. 2012 Aug 3;7:132. doi: 10.1186/1748-717X-7-132

Table 1.

Patient Characteristics

Characteristics (N=62)   n (%)
Age (years)
 
 
 Median (range)
66 (37–93)
 
Sex
 
 
 Female
 
32 (52)
 Male
 
30 (48)
Karnowsky PS
 
 
 Median (range)
40 (20–80)
 
 ≤ 40
 
32 (52)
 ≥ 50
 
30 (48)
Site*
 
 
 Bladder
 
10 (16)
 Lung (NSCLC)
 
9 (15)
 Endometrial
 
8 (13)
 Prostate
 
6 (10)
 Cervical
 
6 (10)
 Gastric
 
6 (10)
 Ovarial
 
6 (10)
 Colorectal
 
3 (5)
 Others#
 
8 (13)
Histology+
 
 
Adenocarcinoma
 
38 (65)
Squamous cell carcinoma
 
6 (10)
Transitional cell carcinoma
 
9 (15)
 Others
 
6 (10)
Tumor-classification+
 
 
T0
 
2 (3)
T3
 
2 (3)
T4
 
55 (94)
Metastasis+
 
 
No
 
1 (2)
Yes
 
52 (88)
Unknown
 
6 (10)
Liver metastasis+
 
 
No
 
43 (73)
Yes
 
16 (27)
Bleeding Site+
 
 
Primary tumor
 
48 (81)
Metastasis
 
11 (19)
Symptom
 
 
 Vaginal bleeding
 
19 (31)
 Hematuria
 
17 (27)
 Hemoptysis
 
10 (16)
 Others
 
16 (26)
First diagnosis to hRT (months)
 
 
 Median (range) 11 (0.3-183)  

Abbreviations: PS=performance status; NSCLC=non-small+ cell lung cancer; hRT=hemostatic radiotherapy; *Site of the primary tumor; # including esophageal (n=2), sarcoma (n=1), multiple myeloma (n=1), kidney cancer (n=1), non-hodgkin lymphoma (n=1), breast cancer (n=1) and pseudomyxoma peritonei (n=1)+. Three patients were not applicable having stage IV non-hodgkin lymphoma according to Ann Arbor (n=1) or stage III multiple myeloma according to Durie and Salmon (n=1) or benign pseudomyxoma peritonei (n=59).